News Hub | News Direct

Healthcare

Addiction Biotech Cannabis Genetics Healthcare Medical Devices Pharmaceutical Science Veterinary
Article thumbnail News Release

Local Lab Campaigns for Science-Backed Cannabis Policies, Business Practices

MCR Labs

Local cannabis testing and research laboratory MCR Labs will be leading open discussions on how to better inform cannabis policies, legislature, and cultivation through the use of data and science. As one of the first independent cannabis testing labs to be established in Massachusetts with the largest cannabis data set on the east coast, MCR Labs is uniquely positioned to guide these conversations. MCR Labs will host several events centered around sensible policy-making and industry standards. The campaign will culminate with MCR’s annual Cannabis Science Fair, showcasing the latest exciting cannabis research and innovation. “What we really need to get away from, especially on a legislative level, is allowing special interests and long-time stigmas to get in the way of sensible policy-making that protects consumers and patients,” said MCR Founder Michael Kahn. “It’s time objective data derived from sound science is used to inform this industry.” The campaign, titled “Science Over Stigma,” is sponsored by Boston Cannabis Week, an organization that curates a week of events for cannabis professionals, consumers and industry innovators. Set in September, Boston Cannabis Week will feature Science Over Stigma’s kick-off event “Cannabis Through the Ages” on Monday, September 19. Learn more about the campaign and upcoming events here. About MCR Labs: MCR Labs is one of the longest operational cannabis testing laboratories on the East coast with facilities operating in several legal cannabis markets. We are ISO/IEC 17025:2017 accredited providers of analytical cannabis product testing and R&D services committed to assisting licensed marijuana establishments, patients, researchers, entrepreneurs, and advocates. Our team of chemists and pharmaceutical scientists are dedicated to advancing public health and safety through leading-edge chemical analysis of cannabis products and offering unparalleled guidance and support for partners, regulators, and the communities we serve. For more information visit http://mcrlabs.com. Contact Details Alexandra Gomes +1 508-782-9772 alexandra@mcrlabs.com Company Website http://mcrlabs.com

September 07, 2022 08:00 AM Eastern Daylight Time

Image
Article thumbnail News Release

AliMed, Inc. awarded Pediatric Straps and Positioners agreement with Premier, Inc.

AliMed, Inc.

AliMed, Inc., a Massachusetts-based medical supply manufacturer and distributor, has been awarded a national group purchasing agreement for pediatric straps and positioners with Premier, Inc., and their Performance Group, Kiindo™. Effective June 1, 2022, the new agreement allows Premier members, at their discretion, to take advantage of special pricing and terms pre-negotiated by Premier for pediatric straps and positioners. “AliMed is committed to serving the pediatric community with high-quality healthcare products designed specifically for their needs,” said Adrienne Hamilton, Director of Marketing at AliMed. “We are excited about this agreement and look forward to working with Premier members to help them realize cost savings, improve efficiencies, and support better quality outcomes across the pediatric continuum of care.” With many products tailored to the unique needs of children from neonatal to adolescents, the AliMed contract includes imaging and surgical straps that provide support and stabilization without damaging delicate pediatric skin, surgical positioners appropriately sized to help relieve pressure from head to foot during procedures, and rehab positioners that aid with strengthening motor skills, balance, mobility, feeding, and more. Premier is a leading healthcare improvement company, uniting an alliance of approximately 4,400 U.S. hospitals and 250,000 other providers to transform healthcare. With integrated data and analytics, collaboratives, supply chain solutions, consulting, and other services, Premier enables better care and outcomes at a lower cost. About AliMed AliMed, Inc. manufactures and distributes acute and post-acute medical products and devices. For over 50 years, AliMed has innovated to deliver flexible supply chain solutions with superior service and value-based products focused on the safety and productivity of the healthcare community. AliMed’s broad portfolio of products for domestic and international care providers, dealers, and distributors are designed to improve patient outcomes and experiences from “hospital to home.” Contact Details Katie McKinley, Sr. Marketing Product Manager, ORMI 781-329-2900 x 214 kmckinley@alimed.com

September 06, 2022 09:00 AM Eastern Daylight Time

Image
Article thumbnail News Release

It All Comes Down To Science And Research With The Efficacy Of Jupiter Wellness’s Lineup Of Skin And Hair Treatment Drugs

Jupiter Wellness, Inc.

Today’s consumers are seemingly more health and wellness conscious than ever before. With the increase in social media use, there is even more emphasis placed on personal appearance, with both men and women upping their wellness game be it in skin care, hair care, general health, and wellbeing, or attempting to preserve youthfulness. Jupiter Wellness Inc. (NASDAQ: JUPW), which focuses on making drugs and skin- and hair-care products, is riding on this emerging trend. The company reports that it’s changed its focus and sharpened its vision over the last year in its journey to rebrand itself and transform into a science- and research-backed pharmaceutical company that uses its health-sciences division for the production, testing, and sale of products aimed at the skin, hair and sexual wellness as well as general health. Jupiter‘s development pipeline includes products to address psoriasis, eczema, burns, herpes and cold sores, hair loss and female libido loss. In fact, last year, the company put its money where its mouth is by acquiring certain assets of Applied Biology, a biotech company specializing in skin and hair science that provides clinical research for several of Jupiter Wellness’s proprietary dermatological treatment products. A Diverse Lineup Of Products Jupiter’s top-of-the-line product is its JW-100, which the company says is a novel topical formulation containing CBD and aspartame used for the topical treatment of atopic dermatitis (eczema) and is in direct competition with Pfizer Inc. ’s (NYSE: PFE) Eucrisa. The company is conducting a Phase 3, double-blind, placebo-controlled multicenter trial to evaluate the superiority of JW-100 to Eucrisa (a Food and Drug Administration (FDA)-approved topical drug) in mild-to-moderate eczema, and it is optimistic that JW-100 may prove superior to Eucrisa and other comparable prescription drugs on the market. Market analysis and go-to-market plans are being developed with an anticipated product launch in 2023, according to the company. Another product in Jupiter's development pipeline is RJ-101, a topical treatment for female libido loss that was discovered when the drug was being used to treat breast cancer and chemotherapy patients who reported an increase in sexual desire as an unexpected side effect. Jupiter has continued clinical trials and reports that RJ-101 increased nipple erection, sensitivity, and genital lubrication in healthy patients as well as those with nipple neuropathy. Jupiter plans to launch RJ-101 in 2023, this product may go both the FDA route as a prescription drug or as a consumer product for female libido loss and potentially as a product for general sexual wellness and pleasure for women. Jupiter’s Minoxidil Booster is an over-the-counter drug used to treat of hair loss. It reportedly works by enriching the sulfotransferase enzyme in the hair and amping up the efficacy of Minoxidil for hair loss. Jupiter says it has licensed its Minoxidil Booster to Taisho, a $2.6 billion Japanese company that is the leading seller of minoxidil products in Japan. Taisho expects to launch the product commercially in 2023. The company’s other skin-care products include Photocil, a topical treatment for psoriasis and vitiligo; JW-300, a topical used to treat first-degree burns and sun exposure; JW 400, a product for treating herpes labialis (cold sores); and NoStingz, a unique sunscreen that protects the skin from jellyfish stings, sea lice, and UVA/UVB rays. NoStingz has been available since April through Amazon.com Inc. (NASDAQ: AMZN), Walmart Inc. (NYSE: WMT), and other select stores with sales growing steadily month over month, according to the company. The company reported revenue of $3.7 million in the first half of 2022. “I am pleased to report that Jupiter Wellness is on track with its 2022 roadmap,” Jupiter Wellness CEO Brian John said. “Jupiter finished the first half of 2022 with momentum and our strongest revenue numbers to date”. Learn more about Jupiter Wellness here. We support health and wellness through the research and development of over-the-counter (OTC) products and intellectual property. Our product pipeline addresses a range of conditions, including hair loss, eczema, burns, and sexual wellness. Revenue is generated through the sales of OTC and consumer products, contract research agreements, and licensing royalties. This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice. Contact Details TraDigital IR- Camille Baptiste camille@tradigitalir.com Company Website https://jupiterwellness.com/

September 06, 2022 08:55 AM Eastern Daylight Time

Article thumbnail News Release

Is Growing Awareness Of Good Oral Hygiene Driving Growth Of Electric Toothbrush Market?

Bruush Oral Care Inc.

Learn More about Bruush Oral Care Inc., by gaining access to the latest research report. The debate over whether electric or manual toothbrushes do a better job of cleaning your teeth has raged for decades. While both manual and electric toothbrushes are effective at removing plaque, powered toothbrushes often are easier for people who have dexterity issues, such as the elderly, people with disabilities or children, according to the American Dental Association (ADA). The Journal of the American Dental Association published a survey that found that 13,000 out of 16,000 patients who used an electric toothbrush reported better oral health. Still, only 36% of adults say they use an electric toothbrush, according to a report by consumer marketing analysis firm Mintel. The global electric toothbrush market size was estimated to be worth $4.3 billion in 2022 and projected to increase to just over $6 billion by 2027, according to Statista. The market is being driven by the prevalence of periodontal diseases and heightened awareness of the advantages of electric toothbrushes. Electric toothbrush bristles vibrate or rotate to remove plaque buildup from teeth and gums. There are pros and cons to an electric toothbrush. On the plus side, they’re easy to use; most have timers so users can tell whether they’ve brushed their teeth for the full two minutes dentists recommend, and some people feel that their teeth are cleaner. “If you choose an electric toothbrush, make sure the toothbrush is comfortable to hold and easy to use,” said Thomas Salinas, a prosthodontist with the Mayo Clinic in Rochester, Minnesota. “Whether you choose an electric toothbrush or a manual toothbrush, remember that what’s most important is daily brushing and flossing.” Electric toothbrushes also may generate less waste. The ADA recommends replacing your toothbrush every three months, and with an electric toothbrush, you’re just replacing the brush head — not the entire device as you would with the manual version. What Are The Drawbacks? However, electric toothbrushes are more expensive than their manual counterparts; they require charging, and they’re difficult to travel with. And replacing brush heads can be expensive. Replacement brush heads for Sonicare can cost as much as $43 for a three-pack, and the price of Oral-B line of brush heads reaches as high as $40 for a three-pack, depending on the model. What Is A Solution? An example of a more affordable alternative is the Brüush (NASDAQ: BRSH) electric toothbrush, which comes in five colors. Like Blue Apron Holdings Inc. (NYSE: APRN) and Stitch Fix Inc. (NASDAQ: SFIX), which send their food and clothing products to customers who sign up, Brüush’s subscription model makes it easy for consumers to stay on top of replacing their brush heads every three months as dentists recommend. If you sign up for a subscription, Brüush will send you three new brush heads every six months for $18 — just $6 per brush head. The Brüush toothbrush has six cleaning modes for every type of brusher — daily, white, gentle, gum, max, and tongue. Brüush’s electric toothbrush kit sells for $79 and includes the electric toothbrush, three brush heads, and a USB power adapter and charger. The Brüush lithium-ion battery lasts for four weeks on a single charge, and the compact magnetic case makes traveling with the device convenient. Visit Brüush’s website to learn more about the company and its products. About Bruush Oral Care Inc. Bruush Oral Care Inc. is on a mission to inspire confidence through brighter smiles and better oral health. Founded in 2018, Brüush is an oral care company that is disrupting the space by reducing the barriers between consumers and access to premium oral care products. The Company is an e-commerce business with a product portfolio that currently consists of a sonic-powered electric toothbrush kit and brush head refills. Brüush has developed a product to make upgrading to an electric brush appealing with three core priorities in mind: (i) a high-quality electric toothbrush at a more affordable price than a comparable electric toothbrush from the competition; (ii) a sleek, countertop-friendly design; and (iii) a convenient brush head refill subscription program that eliminates the frustrating experience of purchasing replacement brush heads at the grocery/drug store. The Company is rooted in building a brand that creates relevant experiences and content, with the goal of becoming the go-to oral care brand for millennials and Generation Z.For more information on Bruush Oral Care Inc visit https://bruush.com. This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice. Contact Details TraDigital IR - Colette Eymontt colette@tradigitalir.com Company Website http://www.tradigitalir.com

September 01, 2022 09:15 AM Eastern Daylight Time

Article thumbnail News Release

Obesity And Back Pain: BioRestorative Therapies Inc. Is Working To Address 2 Common Ailments That Plague Americans with a Major Near Term Data Catalyst

BioRestorative Therapies, Inc.

In 2016, Americans spent roughly $380 billion on lower back and neck pain. In the same year, medical costs for adult obesity in the United States were $260.6 billion. That’s why BioRestorative Therapies Inc. (NASDAQ: BRTX) is working to develop treatments for these 2 indications, laser-focusing on obesity and lower back pain. Lower back pain and obesity are major health crises. Lower back pain is the leading cause of disability worldwide, and obesity has been identified as a national security threat by the Department of Defense. With the escalation of both lower back pain and obesity in recent years, companies have realized the market potential for finding ways to improve the lives of those suffering from these conditions. Companies such as Pfizer Inc. (NYSE: PFE), Novo Nordisk (NYSE: NVO) and Vertex Inc.. (NASDAQ: VRTX) seem to have recognized the market potential for potential obesity treatments and are actively looking for the next breakthrough in obesity therapies. FDA Authorizes BioRestorative to Begin Phase 2 Clinical Trials For Chronic Lower Back Pain Indication; Development For Brown Fat Indication Underway BioRestorative Therapies is looking into the viability of BRTX-100 as an alternative to current treatments for chronic lower back pain that manages the pain rather than attacking the root cause such as pain relievers, steroid injections and opioids. The Food and Drug Administration (FDA) has authorized BioRestorative to begin a Phase 2 clinical trial using BRTX-100 to treat persistent lower back pain resulting from pain-causing degenerative discs. Currently, BioRestorative Therapies is actively recruiting patients to participate in the Phase 2 study. More information can be found here https://clinicaltrials.gov/ct2/show/NCT04042844?term=brtx&draw=2&rank=1. Another treatment BioRestorative is developing is ThermoStem, which targets obesity and metabolic disorders through the use of brown adipose-derived stem cells to generate new brown fat tissue. This brown fat tissue has been shown to increase metabolic activity and potentially regulate metabolic dysfunction in mice. New Developments Might Promise Better Health BioRestorative Therapies’ leadership is excited about the company’s ability to continue developing its two major technologies that could potentially provide access to multibillion-dollar markets. The company raised $23 million last November 2021 and is funded to prosecute its phase 2 clinical trial targeting chronic lumbar disc disease. Major Catalyst Near Term BioRestorative plans to unveil major safety data for its new therapies within the first quarter of 2023. Company leadership believes this will be a major catalyst for driving growth because positive safety data would provide acceleration to enrollment in and provide major validation for BRTX-100’s Phase 2 clinical trial for lower back pain. BioRestorative also reports that top key opinion leaders (KOLS) are highly engaged in the company’s research and development and are having their clinical sites participate in BioRestorative’s clinical trial. The Company also reports they are oversubscribed in terms of high-quality clinical site selection. With the company’s recent developments, upcoming safety data reveals and involvement of KOLS, BioRestorative is confident that it is heading in a positive direction and is hopeful it will positively impact the lives of millions. BioRestorative Therapies was founded by scientists and researchers committed to developing stem cell therapies to address unmet needs in patients with highly prevalent conditions.Our advances in stem cell biology and delivery protocols harbor great promise in conditioning our bodies’ own regenerative potential to treat major diseases more effectively than current interventions.Today, BioRestorative is actively developing programs that aim to dramatically increase quality of care for both (i) chronic back pain caused by disc degeneration, as well as (ii) metabolic disorders including obesity and diabetes. This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice. Contact Details Investor Relations ir@biorestorative.com Company Website https://www.biorestorative.com/

September 01, 2022 09:00 AM Eastern Daylight Time

Article thumbnail News Release

SHATTERPROOF TO BRING CHICAGO COMMUNITY TOGETHER FOR RISE UP AGAINST ADDICTION EVENT ON SATURDAY, SEPTEMBER 10

Shatterproof

WHAT: Shatterproof, a national nonprofit focused on reversing the course of the addiction crisis in America, will host an event on Saturday, Saturday 10 for the Chicago community to rise up against addiction and support family, friends, neighbors and colleagues impacted by the disease. The third Rise Up Against Addiction Walk will give the community the opportunity to bring the disease of addiction into the light and share inspiring stories of hope and recovery. Participants will unite to engage in several activities geared toward ending the stigma associated with substance use disorder, including a 5K walk. Other highlights include: • The Shatterproof Community Resource Village, showcasing substance use disorder resources from local organizations • The Memorial Gallery, featuring an area dedicated to photos and stories of lost loved ones • Celebrate Recovery Wall, an interactive space to unite and celebrate with hundreds of others in recovery • An opening ceremony profiling local walkers touched by addiction and recognition of top teams, fundraisers and leading event sponsors Revenues raised from the Rise Up Against Addiction event supports Shatterproof’s work in advocating for changes in federal and state policy as well as programming focused on saving lives and changing the conversation about addiction. **For more information or to register for the Rise Up Against Addiction 5K Walk event, visit: https://fundraise.shatterproof.org/index.cfm?fuseaction=donorDrive.event&eventID=623 WHO: Local families touched by addiction and leading event sponsors. Shatterproof executives: L. Patrick Reedy, CFRE, Chief Development Officer and Kirsten Suto Seckler, Chief Marketing and Communications Officer – Speaking and available for interviews Caitlin Strebing, Shatterproof Ambassador and Chicago Walk Captain who lost her brother to a fentanyl overdose a year ago. – Available for interviews WHEN: Saturday, September 10, 2022 8:00 a.m. Site opens 9:00 a.m. Opening Ceremony begins 9:30 a.m. Walk begins WHERE: Soldier Field 1410 Special Olympics Drive Chicago, IL 60605 About Shatterproof: Shatterproof is a national nonprofit organization dedicated to reversing the addiction crisis in the U.S. Shatterproof harnesses the models of business, the rigor of science and the power of a national movement to create change and save lives through three pillars of work: revolutionizing the addiction treatment system, breaking down addiction-related stigmas and supporting and empowering our communities. Find Shatterproof on Facebook, Twitter and YouTube: @ShatterproofHQ or follow them on Instagram at @weareshatterproof. To learn more, visit www.Shatterproof.org. Contact Details Shatterproof Lauren Lawson-Zilai +1 240-910-5483 press@shatterproof.org Company Website https://www.shatterproof.org/

August 29, 2022 12:32 PM Eastern Daylight Time

Article thumbnail News Release

The Chicago School of Professional Psychology Awarded $260K For Students

The Chicago School of Professional Psychology

The Chicago School of Professional Psychology announced it has been awarded $260,000 as part of the Ronald E. McNair Postbaccalaureate Achievement Program, a federal government initiative for colleges and universities to assist low-income, first-generation college students and individuals with disabilities. The U.S. Department of Education earlier this month set aside $51.7 million in 189 new grant awards to institutions of higher education such as The Chicago School to provide disadvantaged college students effective preparation for doctoral studies. “We are excited to implement new programs that will further set up our students for success in school and in their chosen professions,” said Dr. Michele Nealon, President of The Chicago School of Professional Psychology. “We are deeply invested in enlarging the pipeline of mental health professionals who will go on to work in underserved communities where they are needed most.” Through McNair grant funding, The Chicago School will offer research or other scholarly activities, such as summer internships and seminars to students. McNair-funded initiatives also prepare students for doctoral study through tutoring, academic counseling, and assistance with securing admission to and financial assistance for enrollment in graduate programs. McNair projects may also fund financial and economic literacy of students, mentoring programs, and exposure to cultural events and academic programs not usually available to disadvantaged students. The Chicago School is a majority minority-serving institution serving more than 6,000 students, maintains campuses in six major metro areas and an online program. Two-thirds of its students identify as people of color. About The Chicago School of Professional Psychology Integrating theory with hands-on experience, The Chicago School of Professional Psychology provides education rooted in a commitment to innovation, service, and community for thousands of diverse students across the United States and globally. Founded in 1979, the nonprofit, regionally accredited university now features campuses in iconic locations across the country (Chicago, Southern California, Washington, D.C., New Orleans, Dallas) and online. To spark positive change in the world where it matters most, The Chicago School has continued to expand its educational offerings beyond the field of psychology to offer more than 30 degrees and certificates in the professional fields of health services, education, counseling, business, and more. Through its engaged professional model of education, commitment to diversity and inclusion, and an extensive network of domestic and international professional partnerships, The Chicago School’s students receive real-world training opportunities that reflect their future careers. The Chicago School is proud to be a part of TCS Education System, a nonprofit, integrated system of colleges and universities that work collaboratively to advance student success and community impact. To learn more, visit www.thechicagoschool.edu. Contact Details The Chicago School of Professional Psychology Vivien Hao +1 323-893-4743 vhao@thechicagoschool.edu The Chicago School of Professional Psychology Victor Abalos +1 818-321-5371 vabalos@thechicagoschool.edu

August 26, 2022 06:00 AM Pacific Daylight Time

Article thumbnail News Release

Hong Kong Baptist University scientists develop versatile compound for treating Alzheimer’s disease

Hong Kong Baptist University

HONG KONG SAR - Media OutReach - 24 August 2022 - A study led by researchers from Hong Kong Baptist University (HKBU) has demonstrated that a multifunctional organic compound named F-SLOH has the potential to treat Alzheimer’s disease (AD) at an early stage. The team found that it can inhibit the aggregation of amyloid-beta (Aβ), and reduce the hyperphosphorylation of tau proteins and neuroinflammation in the brain to improve the pathological features of AD. The findings have been published in the international academic journal Redox Biology. The study conducted by Professor Li Min (left), Professor Ricky Wong Man-shing (right) and Dr Iyaswamy Ashok (middle) provides the first in vivo evidence that F-SLOH is an effective agent that can target and treat multiple neurodegenerative changes in an AD mouse model. AD is the most common cause of dementia. It accounts for nearly 65% of dementia cases in elderly Hong Kong Chinese. It is pathologically characterised by the abnormal aggregation of Aβ, the hyperphosphorylation of tau proteins and neuroinflammation in the nerve cells in the brain, which cause progressive neuronal loss and cognitive impairment. Currently there is no cure for AD, and the available medicines can only relieve its symptoms. Inhibiting the abnormal aggregation of Aβ and the hyperphosphorylation of tau proteins is considered the primary and a promising therapeutic approach to treat AD. F-SLOH as theragnostic agent for AD In the search for novel therapeutic and diagnostic methods for AD, a research team comprising Professor Li Min, Professor of the Teaching and Research Division and Associate Dean of the School of Chinese Medicine; Professor Ricky Wong Man-shing, Professor of the Department of Chemistry of the Faculty of Science; and Dr Iyaswamy Ashok, Research Assistant Professor of the Teaching and Research Division of the School of Chinese Medicine at HKBU, demonstrated the in vivo therapeutic efficacy of a compound called F-SLOH in reducing the abnormal aggregation of Aβ, the hyperphosphorylation of tau proteins and neuroinflammation in the nerves cells in the brain, thereby improving the learning and memory functions of mice with AD. F-SLOH is a multi-functional cyanine probe synthesised by a team led by Professor Ricky Wong Man-shing for the detection of biological materials such as proteins and peptides. Its features include real-time visualisation of Aβ aggregation in brains, excellent permeability across the blood-brain barrier and low bio-toxicity. Previous studies showed that F-SLOH could inhibit the abnormal aggregation of Aβ species and provide neuroprotection against neurotoxicity induced by the abnormal aggregation of Aβ in vitro at the cellular level. F-SLOH improves pathological features in AD mice To determine the therapeutic efficacy of F-SLOH for AD, the researchers injected or fed F-SLOH to a group of transgenic AD mice. Histopathology and biochemical analyses showed that in mice treated with F-SLOH, Aβ oligomers (one of the Aβ species) and Aβ plaque deposits (the clumps of Aβ) were dramatically reduced in their hippocampus and their brains when compared with the AD mice in the control group who had not been fed F-SLOH. The researchers also found that F-SLOH can reduce the levels of an amyloid precursor protein that generates Aβ and tau protein hyperphosphorylation. In an immunoblot analysis of the transgenic AD mice brian, the F-SLOH treatment group showed a significant reduction in the levels of the amyloid precursor protein and its metabolites compared to the control group. In other experiments on the transgenic AD mice after F-SLOH treatment, the researchers separated the soluble and insoluble tau proteins in their brain tissue samples. The results showed that F-SLOH treatment significantly reduced the levels of insoluble tau protein in the brains of AD mice, which forms neurofibrillary tangles, one of the pathological features of AD. F-SLOH improves memory and cognitive functions in AD mice Aggregation of Aβ is closely related to the dysfunction of the links between nerve cells and memory decline. The researchers conducted two experiments to test the memory functions of AD mice. In the first experiment, mice were trained to swim in a water maze, reach a platform and remember its position. After the platform was removed, researchers observed whether the mice were able to recall and approach the original position of the platform. Compared to the control group, transgenic AD mice treated with F-SLOH spent more time swimming around the platform’s original position, showing that they can better memorise the platform’s location. In the second experiment, mice were placed in a chamber and exposed to an audio tone followed by an instant small electric shock to their feet from the floor of the chamber. On the following day, they were put back in the chamber but without any electric shock. When the mice were exposed to the same audio tone, they “froze” their body movements due to the fear of an electric shock. The transgenic AD mice treated with F-SLOH exhibited a longer freezing time than that of the control group. The results of the two experiments showed that AD mice treated with F-SLOH have better memories compared to the control group, suggesting that F-SLOH improved AD mice’s memory and cognitive functions. F-SLOH shows early potential for treating AD The researchers also revealed that F-SLOH degraded the abnormal aggregation of Aβ and reduced the levels of tau protein hyperphosphorylation, the amyloid precursor protein and its metabolites through the activation of the transcription factor EB. Transcription factor EB is the main regulator of the autophagy-lysosomal pathway, a major mechanism for degrading ageing intracellular macromolecular proteins, including the intracellular metabolites such as Aβ aggregates. Professor Li Min said: “AD patients lose their self-management abilities and require long-term care as the disease progresses. As the population is ageing in Hong Kong, the prevalence of AD is likely to increase. There is an urgent need to develop new drugs that can treat or slow down the progression of AD. The current study suggests that the compound F-SLOH has promising theragnostic potential for treating AD at an early stage.” Professor Ricky Wong Man-shing said: “The study provides the first in vivo evidence that F-SLOH is an effective agent that can target and treat multiple neurodegenerative changes in an AD mouse model. The research findings can drive advancements in AD diagnosis and treatment in humans.” Contact Details Communication and Public Relations Office at HKBU Christina Wu christinawu@hkbu.edu.hk

August 25, 2022 10:52 PM Eastern Daylight Time

Image
Article thumbnail News Release

Giving Metabolism A Boost? BioRestorative Uses Science Surrounding Brown Fat Cells To Provide A Possible Breakthrough In Metabolic Disorders

BioRestorative Therapies, Inc.

In 2017, 41.9% of Americans experienced some level of obesity. Adults experiencing obesity in 2019 spent an average of $1,861 more on medical expenses than people with a healthy weight. For people who experience obesity, the presence of excess fat is a legitimate concern that can cost money, cause additional health problems and be associated with psychological problems such as anxiety, depression and low self-esteem. Some of the health concerns associated with obesity include high blood pressure, high bad cholesterol and low good cholesterol, type 2 diabetes, coronary heart disease, stroke, gallbladder disease and osteoarthritis. Research has found that extreme obesity is associated with suicidal behavior and suicide attempts in adults. With growing data on the impacts of obesity, researchers at organizations like the National Institute of Health and Harvard Medical School have devoted resources to understanding new methods for combatting metabolic disorders such as obesity and type 2 diabetes. Both the National Institute of Health and Harvard Medical School reportedly made an exciting discovery. While fat has often been villainized, what many people may not know is that there are two types of fat cells — brown fat cells and white fat cells. Excessive amounts of white fat can be concerning and may lead to an increased risk for health issues such as heart disease, diabetes and numerous other metabolic diseases. On the other hand, brown fat cells have been found to potentially be an important tool for combating different metabolic diseases. When people with high brown fat activity are exposed to a relatively cold temperature, a protein (SLC25A44) is produced and used as energy in cells to generate heat, which results in burned calories and increased metabolism. When researchers blocked the production of this protein in mice, it was found to increase levels of obesity and signs of diabetes. Researchers found that boosting SLC25A44 activity is a promising strategy for potentially treating conditions such as obesity and diabetes. Companies such as Ember Therapeutics Inc. (NASDAQ: EMBT), Adipo Therapeutics LLC and BioRestorative Therapies Inc. (NASDAQ: BRTX) are actively working to use these scientific studies to combat metabolic diseases. Promising New Treatments One of the treatments developed by BioRestorative Therapies designed to potentially target obesity, diabetes and other metabolic disorders is ThermoStem. BioRestorative says that the ThermoStem program uses brown adipose-derived (otherwise known as brown fat) stem cells to help increase metabolic activity. Previously published studies by BioRestorative have demonstrated that transplanting brown fat can increase metabolic activity and regulate metabolic dysfunction in diet-induced obese mice. BioRestorative Therapies reports it is working on Investigational New Drug Application (IND)-enabling studies to enter into first-in-man clinical studies. Using a cell-based approach to target metabolic disorders may potentially provide a disruptive solution to address a multi-billion market opportunity. While the fight against metabolic disorders such as obesity is far from over, it is hopeful that therapies based on the findings surrounding brown fat, such as ThermoStem may provide relief for many currently struggling. BioRestorative Therapies was founded by scientists and researchers committed to developing stem cell therapies to address unmet needs in patients with highly prevalent conditions.Our advances in stem cell biology and delivery protocols harbor great promise in conditioning our bodies’ own regenerative potential to treat major diseases more effectively than current interventions.Today, BioRestorative is actively developing programs that aim to dramatically increase quality of care for both (i) chronic back pain caused by disc degeneration, as well as (ii) metabolic disorders including obesity and diabetes. This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice. Contact Details Investor Relations ir@biorestorative.com Company Website https://www.biorestorative.com/

August 25, 2022 03:49 PM Eastern Daylight Time

1 ... 161162163164165 ... 236